Abstract
De novo metastatic castration-sensitive prostate cancer (mCSPC) is highly aggressive, but the lack of routine tumour tissue in this setting hinders genomic stratification and jeopardizes precision oncology efforts. Accurate molecular profiling at diagnosis is imperative for genomics-informed risk stratification and biomarker-guided treatment. Currently, it is unclear the extent that intrapatient heterogeneity impacts clinical cancer genotyping.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
